Vivos Therapeutics Inc SEC Filings

Vivos Therapeutics, Inc. reported sharply higher revenue but widening losses for the quarter ended September 30, 2025, while highlighting substantial doubt about its ability to continue as a going concern. Quarterly revenue rose to $6.8 million from $3.9 million a year earlier, driven mainly by growth in service revenue such as sleep testing, treatment centers and billing services. For the nine months, revenue increased to $13.6 million from $11.3 million.

Despite this growth, the company posted a net loss of $5.4 million for the quarter and $14.3 million for the nine months, with higher general and administrative costs and depreciation tied to its expanding operations. Cash and cash equivalents were $3.1 million at September 30, 2025, versus total liabilities of $23.1 million, and stockholders’ equity fell to $2.5 million from $8.0 million at year-end 2024.

Vivos completed an $8.7 million acquisition of The Sleep Center of Nevada, funded partly by an $8.3 million senior secured note and new equity, adding goodwill and intangible assets and expanding its new sleep-center based distribution model. Management notes ongoing operating cash burn of $11.5 million year-to-date and states that existing cash will not fund operations for the next 12 months without additional financing.

Vivos Therapeutics (VVOS) filed a late notice for its Q3 2025 Form 10‑Q, citing the need for additional time to review and consolidate interim financial statements from its newly acquired subsidiary, The Sleep Center of Nevada (SCN), acquired on June 10, 2025. The company expects to file within the five‑day extension permitted under Rule 12b‑25.

Vivos anticipates that revenue increased by over 50% for the three months ended September 30, 2025 versus the prior‑year period, driven primarily by higher sales of Vivos products and services originating from SCN. The company also expects Sales, General and Administrative expenses to rise by over 50%, reflecting salaries, rent and other SCN operating costs, and therefore anticipates a higher net loss year over year. These figures remain under review and may change when the Form 10‑Q is filed.

Vivos Therapeutics reported results from its 2025 annual meeting. Stockholders elected R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow and Dr. Matthew Thompson to one-year board terms. An amendment to the 2024 Omnibus Equity Incentive Plan was approved with 2,453,436 shares for, 516,368 against and 2,275 abstaining. Baker Tilly US, LLP was ratified as independent auditor with 4,861,139 shares for, 102,827 against and 4,762 abstaining.

Voting eligibility totaled 7,504,807 shares outstanding as of September 8, 2025, with a quorum of approximately 4,968,728 shares represented.

Vivos Therapeutics filed a prospectus supplement updating its at-the-market program under its Form S-3. The company may offer and sell common stock with an aggregate offering price of up to $3,583,686 from time to time through H.C. Wainwright & Co., as sales agent, pursuant to General Instruction I.B.6 of Form S-3.

This update reflects current I.B.6 capacity and excludes approximately $4,605,773 of shares previously sold under the prior prospectus. The public float was approximately $35,068,378, calculated from 7,477,266 non‑affiliate shares at $4.69 per share as of August 26, 2025. Over the past 12 months, the company sold securities with an aggregate market value of approximately $8,105,774 under I.B.6. VVOS last traded at $2.97 on October 23, 2025.

Vivos Therapeutics (VVOS) reported that on October 24, 2025 it filed a prospectus supplement to increase the aggregate offering price of shares issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., dated February 14, 2025. This update expands the capacity available for potential future issuances of common stock through the ATM program after effectiveness as permitted by the prospectus supplement.

The company also filed a legal opinion from Ellenoff Grossman & Schole LLP as Exhibit 5.1, with the related consent included in the same exhibit. VVOS’s common stock trades on The NASDAQ Stock Market LLC.

The filing is a Definitive Proxy Statement for Vivos Therapeutics, Inc. (VVOS) containing meeting and governance disclosures. Only stockholders of record as of September 8, 2025 may vote at the Annual Meeting. The board recommends FOR each director nominee in Proposal 1 and FOR Proposals 2 and 3. The company adopted a revised Insider Trading Policy to reflect changes to SEC Rule 10b5-1 effective February 2023, including pre-clearance by the Chief Financial Officer and specified trading windows. Beneficial ownership disclosures show V-CO Investors 2, LLC holds 828,000 shares (11.03%) and Dawei Luo holds 572,016 shares (7.62%). Executive and director group ownership is disclosed as 157,874 shares (2.10%). The filing also lists director nominees, director fees and various outstanding option grants with grant dates, strike prices and expiration dates.